“Impact of Infections in Patients with Acute Myeloid Leukemia Receiving Cytarabine+ Daunorubicin (7+3) Versus Azacitidine and Venetoclax during Induction Chemotherapy”, IJBR, vol. 3, no. 1, pp. 190–196, Jan. 2025, doi: 10.70749/ijbr.v3i1.469.